Literature DB >> 158402

Effects of inflammatory disease on plasma oxprenolol concentrations.

M J Kendall, C P Quarterman, H Bishop, R E Schneider.   

Abstract

When single oral doses of oxprenolol were given to three healthy subjects on three separate occasions under standardised conditions the plasma concentration-time curves for each subject were closely similar. In two of the subjects, however, a mild illness led to a dramatic, temporary increase in the peak plasma concentration and area under the plasma concentration-time curve (AUC). This effect of inflammatory disease was confirmed by comparing a group of patients with an erythrocyte sedimentation rate (ESR) of over 20 mm in the first hour with a group whose ESR was below this value. The mean peak plasma concentration and AUC were significantly higher in the group with a raised ESR. This may be related to altered concentrations of one of the acute-phase proteins. Thus it is concluded that plasma oxprenolol concentrations are raised in inflammatory disease, but further work is needed to determine the mechanism of this increase.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 158402      PMCID: PMC1595972          DOI: 10.1136/bmj.2.6188.465

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  6 in total

1.  Pharmacokinetics of oxprenolol in normal subjects.

Authors:  W D Mason; N Winer
Journal:  Clin Pharmacol Ther       Date:  1976-10       Impact factor: 6.875

2.  Drug binding to alpha 1-glycoprotein.

Authors:  R E Schneider; H Bishop; C F Hawkins; G Kitis
Journal:  Lancet       Date:  1979-03-10       Impact factor: 79.321

3.  A comparison of slow release with conventional oxprenolol: plasma concentrations and clinical effects.

Authors:  M J West; M J Kendall; M Mitchard; E B Faragher
Journal:  Br J Clin Pharmacol       Date:  1976-06       Impact factor: 4.335

4.  Relation between plasma concentrations and cardiovascular effects of oral oxprenolol in man.

Authors:  L Brunner; P Imhof; D Jack
Journal:  Eur J Clin Pharmacol       Date:  1975       Impact factor: 2.953

5.  The metabolites of oxprenolol (Trasicor) in man.

Authors:  W Riess; H Huerzeler; F Raschdorf
Journal:  Xenobiotica       Date:  1974-06       Impact factor: 1.908

6.  Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevations of plasma alpha1 acid glycoprotein.

Authors:  K M Piafsky; O Borgá; I Odar-Cederlöf; C Johansson; F Sjöqvist
Journal:  N Engl J Med       Date:  1978-12-28       Impact factor: 91.245

  6 in total
  12 in total

Review 1.  Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment.

Authors:  E G Quetglas; A Armuzzi; S Wigge; G Fiorino; L Barnscheid; M Froelich; Silvio Danese
Journal:  Eur J Clin Pharmacol       Date:  2015-05-27       Impact factor: 2.953

Review 2.  Clinical pharmacokinetics of beta-adrenoceptor antagonists. An update.

Authors:  J G Riddell; D W Harron; R G Shanks
Journal:  Clin Pharmacokinet       Date:  1987-05       Impact factor: 6.447

3.  Effect of age on plasma propranolol levels.

Authors:  R E Schneider; H Bishop; R A Yates; C P Quarterman; M J Kendall
Journal:  Br J Clin Pharmacol       Date:  1980-08       Impact factor: 4.335

4.  Bupivacaine kinetics during hyperthermia in rats.

Authors:  B Bruguerolle; X Roucoules; L Attolini; A M Lorec
Journal:  Can J Anaesth       Date:  1994-03       Impact factor: 5.063

5.  Effects of acute febrile infectious diseases on the oral pharmacokinetics and effects of nitrendipine enantiomers and of bisoprolol.

Authors:  P A Soons; C Grib; D D Breimer; W Kirch
Journal:  Clin Pharmacokinet       Date:  1992-09       Impact factor: 6.447

6.  Selective effect of adjuvant arthritis on the disposition of propranolol enantiomers in rats detected using a stereospecific HPLC assay.

Authors:  M Piquette-Miller; F Jamali
Journal:  Pharm Res       Date:  1993-02       Impact factor: 4.200

7.  A simple and rapid fluorometric determination method of alpha 1-acid glycoprotein in serum using quinaldine red.

Authors:  H Imamura; T Maruyama; H Okabe; H Shimada; M Otagiri
Journal:  Pharm Res       Date:  1994-04       Impact factor: 4.200

Review 8.  First-pass elimination. Basic concepts and clinical consequences.

Authors:  S M Pond; T N Tozer
Journal:  Clin Pharmacokinet       Date:  1984 Jan-Feb       Impact factor: 6.447

9.  Comparison of pharmacokinetic profiles of single and multiple doses of a slow release Oros oxprenolol delivery system in young normotensive and elderly hypertensive subjects.

Authors:  I D Bradbrook; M Babiker; P Crome; H C Gillies; P J Morrison; H J Rogers; P Shotton
Journal:  Br J Clin Pharmacol       Date:  1986-04       Impact factor: 4.335

10.  The effect of age on the pharmacokinetics of metoprolol and its metabolites.

Authors:  C P Quarterman; M J Kendall; D B Jack
Journal:  Br J Clin Pharmacol       Date:  1981-03       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.